FUJIKURA
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/
Key Differentiating Features of the Fujikura PAAM
The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed in-house using an industry leading SiGe BiCMOS process. The PAAM features extremely low noise figure (NF) characteristics and enables a large link margin for expanded coverage. Tunable true-time-delay-type phase shifters support precise and independent phase and amplitude control over a wide frequency range. The unique phase shifter not only enables simple beam-steering control which allows accurate beam steering with fine resolution, but also allows calibration-free operation making PAAM installation much easier. The phase shifter also maintains the transmitted or received signals undistorted by providing invariant group delay and unchanged beam direction in a wide frequency range. In addition, Fujikura PAAM provides superior digital reconfigurability allowing (1) flexible choices in the trade-off space between NF and linearity --- this enables a wide range of coverage applications simply through digital reconfiguration of the PAAM, and (2) on-chip support for 1000s of beam configurations. These are exactly the features highly desired by 5G wireless equipment manufacturers.
5G mmWave Market Growth
Currently, 5G deployments are accelerating around the world and mmWave bands are expected to play a significant role in enhancing the network capabilities. According to the Global mobile Suppliers Association (GSA), by the end of August, 2020, 397 operators in 129 countries and territories had announced investments in 5G. The deployment of 5G mmWave has started primarily in the US market for FWA and MWA, and we are now in the early stages. Markets are expecting substantial increase in 5G mmWave use cases including both outdoor and indoor deployments around the world. Fujikura will contribute to this market growth and benefit from it by providing 5G mmWave infrastructure customers with best-in-class PAAM products.
“Fujikura is announcing its first 5G mmWave RF-IC products for mobile infrastructure. Fujikura n257/n258/n261 PAAM products leverage field proven 5G mmWave IC1 and antenna in package2 technologies developed at IBM Research and enhanced by a Fujikura-led Joint Development Program3,4 . Leveraging our expertise in antenna design and substrate technologies as well as our long history and expertise in delivering differentiating products to the telecom industry, we are excited to introduce our new PAAM product family,” said Kenji Nishide, Fujikura R&D Managing Executive Officer. “Fujikura’s PAAM sets new benchmarks in terms of performance and low power consumption with the highest level of integration for 5G mmWave RF-ICs, which will contribute to growth and expansion of 5G mmWave networks and services.”
Product Introduction Schedule
Fujikura will provide samples for early access customers by the end of 1Q 2021 with volume production in 2H 2021.
For More Information
Please visit our website (https://mmwavetech.fujikura.jp/#area-28ghz-module
) and contact us.
About Fujikura
Fujikura Ltd. is a Tokyo-based company that has been providing wires and cables—“Tsunagu,” or connecting, technologies— to build social infrastructure since its foundation in 1885. With this expertise cultivated over 130 years, we commit to contribute to building social infrastructure by developing products for optical fibers, broadband wireless transmission, superconducting wires, electric vehicles, and other advanced technologies. Fujikura Group has approximately 57,000 employees in more than 30 countries, and posted sales revenue of US$6,178.7 million in Fiscal 2019. Find out more at www.fujikura.co.jp/eng
.
Reference
[1] https://www.ibm.com/blogs/research/2018/02/isscc-lewis-winner-award/
[2] https://www.ibm.com/blogs/research/2017/06/using-air-cavity-boost-performance-5g-antenna-module/
[3] https://www.fujikura.co.jp/eng/newsrelease/products/2058964_11777.html
[4] https://mmwavetech.fujikura.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 15:10:00 CEST | Press release
65 Dental Practices Demonstrate Clear ROI With a Clinician-Designed AI Workflow: Zero Missed Calls, Reduced Frontline Workload, Faster Patient Care and Measurable Returns at ScaleThe Results Build on Wildix’s Recent Launch of Wilma AI, the Embedded Agentic AI Layer Behind its Secure, Scalable UCaaS Platform Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed S
KBS Partners with Rimini Street to Accelerate its AI Vision17.9.2025 15:00:00 CEST | Press release
Korea’s public broadcasting network prioritizes funding new AI initiatives instead of costly SAP upgrades by leveraging Rimini Support™ for SAP Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Korean Broadcasting System (KBS) has partnered with Rimini Street to provide support for its SAP ECC 6.0, a strategic move that has helped to fund and accelerate its AI vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917964406/en/ KBS Partners with Rimini Street to Accelerate its AI Vision Central to KBS’s AI-enabled future is the valuable data stored in its core SAP system, a source that encompasses more than 20 years of information unique to the organization. Drawing upon this rich resource, KBS plans to create multiple AI projects and ongoing
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom